{"id":607125,"date":"2022-07-07T12:46:01","date_gmt":"2022-07-07T12:46:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=607125"},"modified":"2022-07-07T12:46:01","modified_gmt":"2022-07-07T12:46:01","slug":"schizophrenia-market-trends-analysis-clinical-activities-leading-companies-emerging-therapies-growth-opportunities-challenges-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/schizophrenia-market-trends-analysis-clinical-activities-leading-companies-emerging-therapies-growth-opportunities-challenges-and-epidemiology-forecast_607125.html","title":{"rendered":"Schizophrenia Market Trends Analysis, Clinical Activities, Leading Companies, Emerging Therapies, Growth Opportunities, Challenges, and Epidemiology Forecast"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1657171353.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Schizophrenia Market Trends Analysis, Clinical Activities, Leading Companies, Emerging Therapies, Growth Opportunities, Challenges, and Epidemiology Forecast\" src=\"https:\/\/www.abnewswire.com\/uploads\/1657171353.jpeg\" alt=\"Schizophrenia Market Trends Analysis, Clinical Activities, Leading Companies, Emerging Therapies, Growth Opportunities, Challenges, and Epidemiology Forecast\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cSchizophrenia Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Schizophrenia, historical and forecasted epidemiology as well as the Schizophrenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\"><strong>Schizophrenia Overview:<\/strong><\/p>\n<p style=\"text-align: justify;\">Schizophrenia is a serious mental illness that interferes with a person&rsquo;s ability to think clearly, manage emotions, make decisions, and relate to others. It is a complex, long-term medical illness, affecting about one percent of Americans. Although schizophrenia can occur at any age, the average age of onset tends to be in the late teens to the early twenties for men, and the late twenties to early thirties for women. It is uncommon for schizophrenia to be diagnosed in a person younger than 12 or older than 40.<\/p>\n<p style=\"text-align: justify;\">Schizophrenia isn&rsquo;t caused by just one genetic variation, but by a complex interplay of geneticsand environmental influences. While schizophrenia occurs in 1% of the general population,having a history of family psychosis greatly increases the risk. Schizophrenia occurs at roughly10% of people who have a first-degree relative with the disorder, such as a parent or sibling.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight has launched a new report on &#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/schizophrenia-market-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Schizophrenia Market<\/a> Insights, Epidemiology, and Market Forecast-2032&rdquo;.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &ldquo;Schizophrenia Market Insights, Epidemiology, and Market Forecast-2032&Prime; report offers an in-depth understanding of the Schizophrenia, historical and forecasted epidemiology as well as the Schizophrenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Schizophrenia Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The total prevalent population of schizophrenia in the 7MM was 5,969,144 in 2021&nbsp;<\/li>\n<li>The total diagnosed prevalent population of schizophrenia in the 7MM was observed to be 3,043,148 in 2021&nbsp;<\/li>\n<li>According to the studies, the majority of cases of Schizophrenia are male as compared to female, in the US and EU-5. But in Japan, the diagnosed cases females represent the majority of the cases&nbsp;<\/li>\n<li>In the epidemiology model of schizophrenia, there are multiple age groups referred ranging from 18-24 Years; 25-to 34 Years; 35-44 Years; 45-54 Years; 55-64 Years, and 65+ Years for schizophrenia in the United States&nbsp;<\/li>\n<li>EU5 countries occupied approximately 33.8% of the diagnosed patient pool amongst 7MM in 2021<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Request a sample for the Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/schizophrenia-market-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/sample-request\/schizophrenia-market-insight=gpr<\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key benefits of the report:<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Schizophrenia market report covers a descriptive overview and comprehensive insight of the Schizophrenia Epidemiology and Schizophrenia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Schizophrenia market report provides insights on the current and emerging therapies.<\/li>\n<li>Schizophrenia market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Schizophrenia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Schizophrenia market.&nbsp;<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Got queries? Click here to know more about the Schizophrenia Market Landscape&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Schizophrenia Symptoms:<\/strong><\/p>\n<p style=\"text-align: justify;\">With medication, psychosocial rehabilitation, and family support, the symptoms of schizophrenia can be reduced. The common symptoms of Schizophrenia include &ndash;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Delusions<\/li>\n<li>Hallucinations<\/li>\n<li>Disorganized thinking<\/li>\n<li>Negative Symptoms<\/li>\n<li>Lack of emotional expressions<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Schizophrenia Market &nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The dynamics of the Schizophrenia market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Cariprazine, CTP-692, and others during the forecasted period 2019-2032.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Learn more by requesting for sample @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/schizophrenia-market-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Schizophrenia Market Landscape<\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Schizophrenia Pipeline Therapies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Aripiprazole<\/li>\n<li>Brexpiprazole<\/li>\n<li>Cariprazine<\/li>\n<li>CTP-692<\/li>\n<li>Luvadaxistat&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Schizophrenia Pipeline Key Companies:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Otsuka Pharmaceutical<\/li>\n<li>Forest Laboratories<\/li>\n<li>Concert Pharmaceuticals<\/li>\n<li>Neurocrine Biosciences<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis<\/p>\n<p style=\"text-align: justify;\">4. Schizophrenia Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Schizophrenia Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Schizophrenia Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Schizophrenia Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Schizophrenia&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Schizophrenia Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Schizophrenia Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Schizophrenia Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Schizophrenia Market Analysis (2018&ndash;2030)<\/p>\n<p style=\"text-align: justify;\">14. Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Market drivers<\/p>\n<p style=\"text-align: justify;\">16. Market barriers<\/p>\n<p style=\"text-align: justify;\">17. Appendix<\/p>\n<p style=\"text-align: justify;\">18. Schizophrenia Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Click here to read more about <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/schizophrenia-market-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Schizophrenia Market Outlook 2032<\/a><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=schizophrenia-market-trends-analysis-clinical-activities-leading-companies-emerging-therapies-growth-opportunities-challenges-and-epidemiology-forecast\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +91 9568243403<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=schizophrenia-market-trends-analysis-clinical-activities-leading-companies-emerging-therapies-growth-opportunities-challenges-and-epidemiology-forecast\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight\u2019s \u201cSchizophrenia Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Schizophrenia, historical and forecasted epidemiology as well as the Schizophrenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/schizophrenia-market-trends-analysis-clinical-activities-leading-companies-emerging-therapies-growth-opportunities-challenges-and-epidemiology-forecast_607125.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[447,405,417,406,423],"tags":[],"class_list":["post-607125","post","type-post","status-publish","format-standard","hentry","category-Education","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/607125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=607125"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/607125\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=607125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=607125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=607125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}